Synairgen starts dosing inhaled COVID-19 drug in phase 3 trialUK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after Share XSynairgen starts dosing inhaled COVID-19 drug in phase 3 trialhttps://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/
Synairgen’s inhaled drug cuts chances of COVID-19 progressingAn inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more Share XSynairgen’s inhaled drug cuts chances of COVID-19 progressinghttps://pharmaphorum.com/news/synairgens-inhaled-drug-cuts-chances-of-covid-19-progressing/
Synairgen doses first patients with COVID-19 drugUK biotech Synairgen has started dosing patients in its phase 2 trial of SNG001, an inhaled formulation of Share XSynairgen doses first patients with COVID-19 drughttps://pharmaphorum.com/news/synairgen-doses-first-patients-with-covid-19-drug/
Duo of UK firms announce coronavirus therapy trialsTwo UK firms have announced plans to begin trials of therapies to tackle the coronavirus outbreak. Synairgen, based Share XDuo of UK firms announce coronavirus therapy trialshttps://pharmaphorum.com/news/duo-of-uk-firms-announce-coronavirus-therapy-trials/
Synairgen under the weather after AZ halts asthma trialAZ assessing drug’s future following trial disappointment. Share XSynairgen under the weather after AZ halts asthma trialhttps://pharmaphorum.com/news/synairgen-setback-az-halts-asthma-trial/